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ApoptosisInsulin is a key hormone regulating glucose homeostasis, intimately associated with glycemia and is exposed to
glycation by glucose, reducing sugars and other highly reactive carbonyls, particularly in diabetes. Glycation of
insulin has been reported to differentially affect protein structure, stability and aggregation depending on the
glycating agent and experimental conditions. Under reducing conditions glycation produces higher insulin
oligomerization thus accelerating amyloid formation whereas, in non-reducing conditions, glycation inhibits
amyloid formation. To better detail the effect of glycation on insulin malfunction and toxicity, we investigated
the effect of another glycating agent, the D-ribose. Recently, ribosylation has received great interest due to its
role in protein glycation and its consequential effects such as protein aggregation, oxidative stress and cell
death. Moreover, unusual high concentration of D-ribose has been detected in the urine of type II diabetics.
Our results show that, using ribose, as glycating agent, the insulin conformation is preserved and does not evolve
in amyloid aggregates because of the block of the α-helix to β-sheet transition, which initiates the aggregation
process, maintaining the protein in a soluble state. At the same time, ribose-glycated insulin strongly affects
the cell viability, starting a death pathway consisting in the activation of caspases 9 and 3/7, intracellular ROS
production and activation of the transcription factor NF-kB.
© Published by Elsevier B.V.20151. Introduction
Insulin is a key hormone regulating glucose homeostasis and a
widely used drug for treatment of diabetes. Insulin is composed of
two peptide chains, the A chain and the B chain, linked by two disulﬁde
bonds. The A chain consists of 21 amino acids organized in two
α-helices connected by a loop and contains an intra-molecular disulﬁde.
The B chain consists of 30 amino acids organized in an α-helix in the
central region of themolecule ﬂanked by two turns and ﬂexible regions
in both termini [1].
Insulin is stored in the pancreas as inactive zinc hexamer; when
released into the blood serum, the hexameric form dissociates into a
dimer and then subsequently into a monomer, which is the physiologi-
cally active form [2]. However, the insulin monomer is less stable than
the hexamer and tends to aggregate forming amyloid aggregates [3,4].
Insulin is able to form amyloid-like ﬁbrils in the site ofmedication injec-
tions of insulin-dependent diabetic patients causing a pathological
condition, called insulin injection amyloidosis [5–9]. A variety ofistry, Biophysics and General
7, 80138 Naples, Italy.
).human diseases including neurodegenerative diseases, are related to
the formation of protein aggregates, named amyloid ﬁbrils [4,10].
Amyloid ﬁbrils are characterized by a common structural motif, the
cross-β-structure in which individual strands in the β-sheets run per-
pendicular to the long axis of the ﬁbril. Insulin has been widely used
as a model protein for the study of the amyloid formation. In fact,
under speciﬁc conditions, i.e., high temperature and low pH, it is very
prone to form amyloid ﬁbrils [11–12]. At pH 2, insulin forms soluble
assemblies in equilibrium with monomers and smaller oligomers [13].
At high temperatures, these species further assemble into larger irre-
versible aggregates and eventually in amyloid ﬁbrils. Theα to β- transi-
tion seems to occur only upon ﬁbril assembly, while the initial
aggregates retain their predominantly helical structure [14–15].
Insulin is associated with glycemia and can be susceptible to
glycation by glucose and other highly reactive carbonyls especially in di-
abetic conditions [16]. Glycated insulin is unable to regulate glucose ho-
meostasis in vivo and to stimulate glucose transport and adipose tissue
lipogenesis [17–19]. Protein glycation is a non-enzymatic, irreversible
modiﬁcation resulting from a chemical reaction of reducing sugars
with primary amino groups (N-terminal, and arginine and lysine side
chains). Spontaneous glycation includes the reversible formation of a
Schiff base which is transformed into a product of Amadori, which can
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[20–21]. Accumulation of AGEs has been suggested to be a main factor
responsible for diabetes-associated complications, such as retinopathy,
nephropathy, atherosclerosis [22–28]. In addition, AGEs have been re-
cently linked to amyloid based neurodegenerative diseases [29–30].
Different proteins associated with these diseases, such as ß-amyloid,
tau, prions and transthyretin, have been found to be glycated in patients
[31–34], suggesting a possible role of glycation in amyloid pathogenesis.
Moreover, glycation of proteins has been reported to destabilize the na-
tive state and stimulate protein aggregation as well as amyloid deposi-
tion [35–43]. Other studies suggest that glycation in proteins does not
promote modiﬁcations in the secondary structure but rather stabilizes
the native conformation inhibiting aggregation [44–47]. However, the
mechanism by which glycation modulate protein aggregation is still
poorly understood. According to the type of reacting sugar, the target
protein undergoes speciﬁc modiﬁcations that may either increase or
suppress protein ﬁbrillation.
In physiological conditions, kinetics of AGE formation is quite slow,
while in diabetes their formation dramatically increases due to the
chronically high concentration of blood sugar [26,48-51]. AGEs damage
cells by affecting the structure and function of proteins as well as
interactingwith speciﬁc cellular receptors, between them the best char-
acterized is the one for AGE (RAGE). High concentrations of AGEs, as ob-
served in diabetes, led to an increased expression of the receptor in cells
of the blood vessel wall, including endothelium and vascular smooth
muscle cells, and promote invasion of circulating immune cells
[27,52]. Activation of RAGE is tightly connected to the sustainment of
the inﬂammatory response, resulting in chronic inﬂammation, as ob-
served in diabetes. The interaction of AGEs with RAGE triggers a range
of cellular responses, including transcription factor activation and changes
in gene expression. Binding of ligands to RAGE results in the activation of
NADPH-oxidases that leads to an increased production of reactive oxygen
species (ROS). One major downstream target of RAGE is the pro-
inﬂammatory NF-kB-pathway, which in turn leads to elevated RAGE
expression and perpetuation of the cellular inﬂammatory state [53-55].
Glycation of insulin has been reported to differentially affect protein
structure, stability and aggregation depending by glycating agent and/
or environmental conditions. In vitro experiments have shown that in-
sulin can be glycated by glucose able to react with Lys29 in the C-
terminal region of chain B and with N-terminus of chains A and B [56,
57]. Glucose induces the formation of glycated insulin adducts having
different structural features depending on the experimental conditions
used. In particular, glycation in reducing conditions is able to induce in-
sulin oligomerization thus accelerating amyloid formation. On the con-
trary, glycation in non-reducing conditions strongly inhibits amyloid
formation in a way proportional to the glycation extent [58]. The effects
of glycation by methylglyoxal on the structure and ﬁbril-forming prop-
erties of insulin have been also investigated [46]. Human insulin can be
glycated also bymethylglyoxal able to react with a single site, i.e., Arg22
of the B-chain. This modiﬁcation promotes the formation of native-like
aggregates and reduces the ability of human insulin to form ﬁbrils by
impairing the formation of the seeding nuclei. These aggregates are
small, soluble, non-ﬁbrillar and retain a native-like structure [46].
In this paper, to clarify the effect of glycation on insulin malfunction
and toxicity, we report the effect of another glycating agent, the
D-ribose, in comparisonwithMG, on the structure and aggregation pro-
pensity.Moreover,we analyze the effect of ribosylated insulin on cell vi-
ability. Recently, an increasing interest has been focused on protein
ribosylation due to its role in protein glycation and its consequent ef-
fects such as protein aggregation and ROS production [59]. Moreover,
abnormally high concentration of D-ribose has been recently found in
the urine of type II diabetic patients [60]. Our results show that both
glycating agents used, by blocking theα-helix toβ-sheet transition, pre-
serve the insulin conformation unable to evolve in amyloid aggregates.
Thus, AGE formation inhibits amyloid aggregation in human insulin
but strongly affects the cell viability. Molecular bases of cell toxicityinduced by AGEs upon ribosylation of human insulin have been also
investigated.
2. Materials and methods
2.1. Materials
Thioﬂavin T (ThT), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra-
zolium bromide (MTT), D-ribose, 2′,7′-dichloroﬂuorescin diacetate, N-
acetylcysteine (NAC), human insulin, methylglyoxal, (Sigma-Aldrich
Co., St. Louis, MO). Uranil acetate replacement stain (ElectronMicrosco-
py Sciences, Hatﬁeld, PA). Primary antibodies: rabbit anti NF-kB p65
(C22B4 Cell Signaling Technology, Danvers, MA), rabbit anti α-tubulin
(ab4074, Abcam), rabbit anti HistoneH1 (ab61177, Abcam), mouse
anti Vimentin (Sigma-Aldrich Co., St. Louis, MO). Secondary antibodies:
Alexa Fluor 488 and Alexa Fluor 633 (Life Technologies Italia, Monza,
Italy). All other chemicals were of analytical grade. Methylglyoxal was
further puriﬁed by distillation under low pressure and its concentration
was determined spectrophotometrically using ε284 = 12.3 M−1 cm−1
[61].
2.2. Insulin preparation and glycation
Human insulin was dissolved in ultra-pure milliQ water to a ﬁnal
concentration of 4 mg/mL, acidiﬁed to a pH of 4 in order to obtain mo-
nomeric insulin and protein concentration determined by absorbance
(ε275 = 4560 M−1 cm−1). Finally, insulin was neutralized to pH 7.0
and kept in phosphate buffer 50 mM, pH 7.0.
Glycated insulin was prepared by mixing human insulin at a ﬁnal
concentration of 2 mg/mL in 0.5 M D-ribose or 5 mM methylglyoxal in
50 mM NaH2PO4 buffer, pH 7.0, passed through a 0.22 μm ﬁlter and in-
cubated at 37 °C in sterile conditions. Human insulin in buffer without
glycating agent was used as protein control. A control sample having
the same amount of glycating agent but with buffer was incubated
under identical conditions.
For aggregation studies, protein samples were incubated at 37 °C
under vigorous stirring with teﬂon balls, 1/8″ diameter (Polysciences,
Inc.). Aliquots were collected in sterile conditions and immediately
analyzed.
2.3. Fluorescence measurements
Fluorescence measurements were performed on a Perkin Elmer Life
Sciences LS 55 spectroﬂuorimeter. To assess the intrinsic ﬂuorescence of
AGEs (λex 320nm/λem 410 nm), glycated insulin at aﬁnal concentration
of 8 μMwas monitored at different incubation times with the glycating
agent. Theﬂuorescence intensitywas corrected by subtracting the emis-
sion intensity of D-ribose/methylglyoxal solutions at different incuba-
tion times. Tyrosine emission ﬂuorescence spectra were recorded
between 280 and 450 nm using a λex of 275 nm. ThT ﬂuorescence
(λex 450 nm/λem 482 nm) was monitored at different time intervals
after addition of ThT to protein samples. Working concentrations were
8 μM for protein samples and 25 μM for ThT. The ThT ﬂuorescence
was corrected by subtracting the emission intensity of glycated samples
before the addition of ThT.
2.4. Circular dichroism (CD)measurements
CD spectra were recorded at 25 °C on a JascoJ-715 spectropolarime-
ter using thermostated quartz cells of 0.1 cm. Spectral acquisition was
taken at 0.2 nm intervals with a 4 s integration time and a bandwidth
of 1.0 nm. An average of three scans was obtained for all spectra.
Photomultiplier absorbance did not exceed 600 V in the spectral region
analyzed. All measurements were performed under nitrogen ﬂow and
spectra were recorded after diluting six times the stock solution (ﬁnal
protein concentration 0.3 mg/mL). Data were corrected for buffer
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Software version 1.00) and transformed in mean residue ellipticity
before analysis. Protein secondary structure estimation was performed
using CDPro software, which contains three software packages,
i.e., CDSSTR, CONTIN/LL, and SELCON3 [62].
2.5. Gel electrophoresis (PAGE)
The glycation-induced oligomerization was monitored by the pro-
tein mobility shift on both native-PAGE and SDS-PAGE (18%) using
Bio-Rad (USA) electrophoresis equipment. Ten micrograms of protein
sample was loaded and the protein bands were stained with Coomassie
Brilliant Blue.
2.6. Immunoblotting
Proteins were separated by 10% SDS-PAGE under reducing condi-
tions, and blotted onto a polyvinylidene diﬂuoride membrane in trans-
fer buffer (25 mM Tris, 192 mM glycine, 20% methanol, 0.1% SDS). The
blots were then probed with primary antibodies, followed by the corre-
sponding horseradish peroxidase (HRP)-conjugated secondary anti-
bodies. Immunoreactivity was detected by the ECL reaction (RPN2109,
GE Healthcare) and quantiﬁed using the ChemiDocMP Imager Software
(Biorad).
2.7. Transmission electronic microscopy (TEM)
Aliquots of protein samples (3 μL) were placed on the copper grid
and allowed to dry. After 5–6 min uranil acetate replacement stain 1×
(3 μL) was loaded on the grid and air dried. Images were acquired
using a Libra 120 (Zeiss) Transmission Electron Microscope equipped
with Wide-angle Dual Speed CCD-Camera sharp:eye 2 K (4Mpx.).
2.8. Cell cultures and treatments
NIH-3T3 mouse embryonic ﬁbroblasts (ATCC# CCL-92) were
cultured in Dulbecco's modiﬁed eagle's medium (DMEM)-high glu-
cose supplemented with 10% bovine calf serum, 3.0 mM glutamine,
50 units/mL penicillin and 50 mg/mL streptomycin in a 5.0% CO2 hu-
midiﬁed environment at 37 °C. CPAE endothelial cells (ECs) (ATCC#
CCL-209) were cultured in Minimun Essential Medium (MEM) supple-
mented with 10% fetal bovine calf serum (USA Origin), 2.0 mM gluta-
mine, 100 units/mL penicillin and 100 mg/mL streptomycin in a 5.0%
CO2 humidiﬁed environment at 37 °C. For all experiments, cells in
culture medium without protein and in the presence of non-glycated
insulin served as control. Before incubation with cells, human insulin
glycated in the presence of 0.5 M D-ribose for 8 days was subjected to
dialysis in sterile conditions to remove the free glycating agent.
2.9. Cell viability assay
Cell viability was assessed as the inhibition of the ability of cells to
reduce themetabolic dye 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltet-
razolium bromide (MTT) to a blue formazan product [63,64]. NIH-3T3
cells were plated at a density of 100,000 cells/well on 12-well plates
in 1 mL of medium. EC were seeded in 96-well at a density of
4000cells/well. After indicated times of incubation with protein sam-
ples, cells were rinsed with phosphate buffer solution (PBS). A stock so-
lution of MTT (5 mg/mL in PBS) was diluted ten times in cell medium
and incubated with cells for 3 h at 37 °C. After removing the medium,
cells were treated with isopropyl alcohol, 0.1 M HCl for 20 min. Levels
of reduced MTT were assayed by measuring the difference in absor-
bance at 570 and 690 nm. Data are expressed as average percentage
reduction of MTT with respect to the control ±S.D. Data are an average
from ﬁve independent experiments carried out in triplicate.2.10. Detection of intracellular ROS
Intracellular ROS were detected by means of an oxidation-sensitive
ﬂuorescent probe 2′,7′-dichloroﬂuorescin diacetate (DCFH-DA). ECs
were grown in a six-well plates, pre-incubated with DCFH-DA for
30 min and then incubated with protein samples for 12, 24, 48, and
72 h. Control experiments were performed using untreated cells and
cells exposed to a 0.001 M H2O2. Experiments in the presence of NAC
were performed on cells pre-treated with 20 mM NAC for 1 h. After
incubation, cells were washed twice with PBS buffer and then lysed
with Tris–HCl 0.5 M, pH 7.6, 1% SDS. The non-ﬂuorescent DCFH-DA
is converted, by oxidation, to the ﬂuorescent molecule 2′,7′-
dichloroﬂuorescein (DCF). DCF ﬂuorescence intensity was quantiﬁed
on a Perkin Elmer Life Sciences LS 55 spectroﬂuorimeter using an exci-
tation wavelength of 488 nm and an emission wavelength of 530 nm.
Data are expressed as average ± S.D. from ﬁve independent experi-
ments carried out in triplicate.
2.11. Cell-cycle analysis
After 12, 24, 48 and 72 h of incubationwith protein samples (30 μM),
2.5×105 cells were collected and resuspended in 500 μL of hypotonic
buffer (0.1% Triton X-100, 0.1% sodium citrate, 50 μg/mL iodide
propidium, RNAse A). Cells were incubated in the dark for 30 min and
samples were acquired on a FACS-Calibur ﬂow cytometer using the
Cell Quest software (Becton Dickinson) and ModFitLT version 3 soft-
ware (Verity) as previously reported [65,66].
2.12. FACS analysis of apoptosis and caspase assay
Apoptosis was measured by evaluation of the pre-G1 content using
ModFitLT version 3 software (Verity). Caspase activity was detected
within living cells using B-BRIDGE Kits supplied with cell-permeable
ﬂuorescent substrates, following the manufacturer's suggestions. The
ﬂuorescent substrates used were FAM-DEVD-FMK for caspase-3/7;
FAM-LETD-FMK for caspase 8; SR-LEHD-FMK for caspase 9. After 48
and 72 h of incubation with protein samples, cells were collected,
washed twice in cold PBS and incubated for 1 h on ice with the
corresponding substrates. Cells were analyzed using Cell Quest software
applied to a FACS-Calibur (BD). Experiments were performed in biolog-
ical duplicates and values expressed in mean ± SD from ﬁve indepen-
dent experiments.
2.13. Confocal laser-scanning microscopy
Confocal microscope analysis was performed as described [67].
Brieﬂy, cells were ﬁxed with 3% paraformaldehyde and permeabilized
with 0.1% Triton X-100 before incubation with speciﬁc antibodies
against NF-kB (1:100, rabbit) and Vimentin (1:1.000, mouse). Second-
ary antibodies were Alexa Fluor 488 (1:1000) or Alexa Fluor 633
(1:1000). Microscopy analyses were performed using Zeiss LSM 700
confocal microscope equipped with a plan-apochromat X 63 (NA 1.4)
oil immersion objective.
2.14. Cellular nuclear extraction
Control and treated cells (1 × 106 cells) were pelleted by centrifuga-
tion, resuspended in lysis buffer (10 mM HEPES pH 7.5, 10 mM KCl,
0.1 mM EDTA, 1 mM dithiothreitol, 0.5% Nonidet-40 and 0.5 mM
PMSF along with the protease inhibitor cocktail) and allowed to swell
on ice for 15–20 min. Tubes were vortexed to disrupt cell membranes
and then centrifuged at 12,000 g at 4 °C for 10 min. The supernatant
was taken as cytoplasmic extract.
The pelleted nuclei were washed thrice with the cell lysis buffer and
resuspended in the nuclear extraction buffer (20 mM HEPES (pH 7.5),
400 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF with protease
Fig. 2. Effect of glycation on the spectroscopic properties of human insulin. Tyrosine emis-
sion ﬂuorescence (panel A) and absorption (panel B) spectra of human insulin incubated
in the absence (black) and in the presence of D-ribose (light gray) and methylglyoxal
(dark gray) for 8 days. Protein concentration was 8 μM (A) and 40 μM (B). The emission
spectrum was recorded upon excitation at 275 nm.
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collected by centrifugation at 12,000 g for 15 min at 4 °C. Protein con-
centration of the nuclear and cytoplasmic extract was estimated using
Bradford's reagent (BioRad, USA). Cytoplasmic contamination of the nu-
clear fraction was tested by checking tubulin through western-blot
analysis.
2.15. Statistical analysis
For statistical analysis, we used a two-tailed Student's t test with un-
equal variance at a signiﬁcance level of 5% unless otherwise indicated.
3. Results
3.1. Effect of glycation on human insulin
Glycation of a protein results in the appearance of a new ﬂuores-
cence derivative centered at 410 nm (λex = 320 nm) that is widely
used tomonitor the AGE formation [68]. For this reason, insulin samples
were incubated at 37 °C in the presence of D-ribose and changes in its
ﬂuorescence intensity were monitored at different time intervals
(days). The results were compared to those obtained incubating insulin
with methylglyoxal. Fig. 1 shows the time course of the emission inten-
sity at 410 nm of insulin incubated with 0.5 M D-ribose and 5 mM
methylglyoxal. The emission intensity of glycated protein increased
markedly with incubation time. Methylglyoxal was shown to be much
more effective than D-ribose as glycating agent. Indeed, it was able to
induce insulin glycation in a shorter time, i.e., glycation is completed
in about 4 dayswhereasD-ribose requires at least 7 days. Human insulin
alone, used as a negative control, showed no ﬂuorescence at 410 nm.
Also, we analyzed the glycation induced modiﬁcation of intrinsic
ﬂuorescence of insulin. This protein contains only tyrosyl residues as
ﬂuorescence emitter and its spectrum is characterized by the typical
tyrosyl emission centered at 305 nm. The emission spectra of human in-
sulin incubated in the absence and in the presence of D-ribose and
methylglyoxal for 8 days are shown in Fig. 2A. A decrease of ﬂuores-
cence intensity of about 20% was detected in the sample glycated with
D-ribose in comparison with the non-glycated one, whereas a much
stronger reduction of ﬂuorescence intensity (about 45%) was detected
in the sample glycated with methylglyoxal. Intensity variation and/or
maximum shift of ﬂuorescence emission could be produced by
structural changes upon glycation as reported for other glycated
proteins [40,59]. However, tyrosine ﬂuorescence is not very sensitiveFig. 1. Glycation kinetics of human insulin. Protein glycation was monitored by ﬂuores-
cence spectroscopy. Insulin was incubated in the absence (black) and in the presence of
0.5 M D-ribose (light gray) and 5 mM methylglyoxal (dark gray) and samples were
analyzed by ﬂuorescence at different time points. Protein concentration was 8 μM, other
experimental details are described in the Materials and methods section.to conformational changes, no shifts in emission maximum being gen-
erally detected. Reduction of emission intensity could be due to
quenching effect produced by neighboring glycated groups. The appear-
ance of a ﬂuorescence tail centered at 410 nm suggests that an energy
transfer occurs between tyrosyl residues and the glycated group. This
is further conﬁrmed by inspection of the absorption spectrum recorded
upon glycation (Fig. 2B). In fact, the glycated insulin shows an absorp-
tion contribution due to AGE formation at wavelength longer than
300 nm, where tyrosyl residues emit. A similar effect has been detected
for other proteins [69]. The observation that the extent of quenching is
largely different for the two AGE modiﬁed insulin adducts formed
with D-ribose and methylglyoxal suggests that glycating agents react
with different amino groups. A study fromOliveira and coworkers iden-
tiﬁed ArgB22 as the only glycated residue in insulin in the presence of
methylglyoxal [46]. Therefore, we can hypothesize that glycation of
ArgB22 induced by methylglyoxal is responsible of the ﬂuorescence
quenching both of TyrA19 and TyrB16 that are very close to the
ArgB22 in the three dimensional structure of native insulin. Similarly,
glycation of Lys29 in the C-terminal region of chain B and on N-
terminus of chain A [57] may quench the emission of Tyr B26.
In order to follow changes in secondary structure induced by
glycation in human insulin we monitored the dichroic activity in the
far-UV region (far-UV CD). After incubation of insulin at 37 °C in the
presence and in the absence of 0.5MD-ribose and 5mMmethylglyoxal,
samples were analyzed by CD spectroscopy at different time points. As
expected, no difference in the CD activity was detected for the protein
without glycating agent at different incubation times (data not
Table 1
Secondary structure content of human insulin in the absence and in the presence of D-
ribose and methylglyoxal at different incubation times.
Ins Ins/MG Ins/Rib
Day1 Day2 Day4 Day7 Day1 Day2 Day4 Day7
α-helix 0.41 0.32 0.26 0.21 0.21 0.40 0.38 0.35 0.31
β-strand 0.09 0.13 0.15 0.16 0.16 0.09 0.10 0.12 0.12
Turn 0.20 0.21 0.21 0.22 0.22 0.20 0.20 0.21 0.21
Unordered 0.30 0.34 0.38 0.40 0.41 0.31 0.32 0.32 0.36
Analysis was performed as described in theMaterials andmethods section and results are
expressed as percentage.
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tion with D-ribose and methylglyoxal are shown in Fig. 3A and B,
respectively. All spectra exhibited two minima at 208 and 222 nm and
a positive band below 200 nm typical of a α-helical conformation. No
light scattering was detected, indicative of absence of protein aggrega-
tion. Although CD spectra of glycated insulin do not exhibit strong
shape variation compared to the non-glycated protein, the reduction
in the dichroic activity at 222 and 197 nm observed as glycation pro-
ceeds is indicative of loss of α-helical structure. Deconvolution analysis
of the CD spectra conﬁrmed the loss of α-helical structure upon
glycation and a corresponding increase of unordered fraction. In
Table 1 is reported the secondary structure content at different
glycation times. There is a strong correspondence between the estimat-
ed content of secondary structure and the results reported in Fig. 1
clearly indicating that the reduction in the helical content is directly
related to glycation extent.
3.2. Ribosylation and insulin oligomerization
Glycation has been indicated as a contributory factor in the forma-
tion of high molecular weight protein species which originate from
inter molecular cross-links among AGE adducts. [47,58,70,71]. In order
to monitor the increase in the apparent molecular weight of glycated
adducts, ribosylation of human insulin was evaluated by mobility shift
electrophoresis. Both native PAGE and SDS-PAGE were used to analyzeFig. 3. Effect of glycation on the secondary structure of human insulin. Time dependence of
the far-UV CD activity of the human insulin at pH 7.0 in the presence of 0.5 M D-ribose
(panel A) and 5 mM methylglyoxal (panel B). Spectra were recorded at indicated times
and protein concentration was 0.3 mg/mL.samples of insulin at different incubation times (3 and 21 days) in the
absence and in the presence of 0.5 M D-ribose (Fig. 4). In the SDS-
PAGE, the samples incubated with D-ribose did not show bands at
high molecular weight both in the early stage of glycation and after
21 days of incubation, thus indicating that covalent crosslinks are not
formed upon glycation (Fig. 4A). This was further conﬁrmed by native
PAGE (Fig. 4B), which shows the presence of a single band both for
glycated and not glycated insulin. The difference observed in themigra-
tion pattern may be ascribed to a modiﬁcation of the charge/mass ratio
produced by glycation of amino groups. Thus, the glycated insulin ad-
duct exhibits a low propensity for oligomerization. When ribosylated
insulin was analyzed by SDS-PAGE under non-reducing condition (Fig.
4C), only additional faint bands at lowmolecularweightwere observed,
roughly corresponding to insulin dimer and trimer. Being detected only
under non reducing conditions, these low molecular weight species
cannot be ascribed to cross-linked AGEs adducts but to non native disul-
ﬁde bonds. Similar results have been reported for insulin glycated with
glucose in non reducing condition [58].3.3. Ribosylation inhibits amyloid ﬁbrils formation in insulin
Amyloid ﬁbrils formation consists of a series of stages including
aggregation of soluble oligomers as result of non speciﬁc interactions,
formation of protoﬁbrillar structures and their assembly into mature ﬁ-
brils [14,72,73]. Insulin amyloid formation, like other amyloidogenic
proteins, occurs through a nucleation and elongation process. Insulin
preﬁbrillar aggregates (oligomers and protoﬁbrils) have a low content
of beta sheet in comparisonwithmature amyloid ﬁbrils, and act as a nu-
cleation agent to form mature ﬁbrils [74]. It has been shown that the
oligomeric intermediates are the most toxic species compared to the
mature ﬁbrils [71-77]. Human insulin is able to form amyloid aggregates
both in denaturing conditions (i.e. pH 2, 60 °C) and in native conditions
upon perturbation (stirring). To investigate the effect of ribosylation on
the aggregation process of the human insulin, we tested the ability of
glycated insulin to form amyloid aggregates in native conditions upon
stirring. To this aim, human insulin after glycation with D-ribose for
8 days was incubated at 37 °C with stirring and samples were analyzed
at different incubation times by ThT ﬂuorescence (Fig. 5A). The results
were compared to those obtained incubating insulin with 5 mM
methylglyoxal. ThT ﬂuorescence is a widely used method for detecting
amyloid formation as ThT speciﬁcally binds amyloid structures
exhibiting a strong ﬂuorescence increase [78]. As expected, the non-
glycated insulin is able to bind ThT in few hours, thus indicating the for-
mation of amyloid species in a short time upon stirring. On the contrary,
no ThT ﬂuorescence increase was detected for samples glycated with
both D-ribose andmethylglyoxal upon stirring. The ﬂuorescence inten-
sity detected was comparable to that recorded before ThT addition to
the same sample. ThT ﬂuorescence wasmonitored for onemonth with-
out detecting any ﬂuorescence increase. These results suggest that
glycation with both D-ribose and methylglyoxal strongly inhibits amy-
loid aggregation in insulin. Similar results were observed with
methylglyoxal in a previous study that characterized methylglyoxal
modiﬁcation of insulin [46].
Fig. 4.Effect of glycation on the oligomerization of human insulin. Electrophoresis analysis of human insulin incubated in the absence and in the presence ofD-ribose for 3 and 21days at 37
°C. A, B and C represent the reducing SDS gel, native gel, and non-reducing SDS gel, respectively. Lanes 1 and 3 refer to non glycated insulin, lanes 2 and 4 to glycated insulin. Other ex-
perimental details are described in the Materials and methods section.
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by far-UV CD spectroscopy (Fig. 5B). The CD spectrum of non-glycated
sample strongly differs from that recorded for the ribosylated insulin.
In particular, the former showed a very reduced dichroic activity with
a concomitant morphology change typical of the α-β transition occur-
ring upon ﬁbril formation. On the contrary, ribosylated insulin showed
a spectrumcomparable to the one recorded before stirring and reportedFig. 5. Effect of glycation on the amyloid aggregation of human insulin. Human insulin incubate
was incubated with stirring at 37 °C. Samples were analyzed at the indicated incubation time
emission was recorded at 482 nm upon excitation at 450 nm; working concentrations wer
(40 μM), incubatedwith stirring at 37 °C for 24h (after stirring) and before incubationwith stirri
byMTT assay (panel C). Data are expressed as average percentage ofMTT reduction±SD relativ
with fresh insulin was also tested. Other experimental conditions are described in the Materiain Fig. 2. These results indicate that glycation stabilizes the formation of
soluble species blocking the α-helix to β-sheet transition characteristic
of amyloid ﬁbril formation.
Moreover, we evaluated the viability of cells exposed to non-
glycated insulin and ribose-glycated insulin after 24 h of stirring at 37
°C, i.e., under aggregation condition in which the aggregate forms of in-
sulin are not cytotoxic (Fig. 5C). As expected, no toxicity was detectedd in the absence and in the presence of 0.5 M D-ribose and 5mMmethylglyoxal for 8 days
s by ThT ﬂuorescence (panel A), and after 24 h by far-UV CD spectroscopy (panel B). ThT
e: (A) 8 μM for protein samples and 25 μM for ThT; (B) 0.3 mg/mL. Samples of insulin
ng (before stirring),were exposed toNIH-3T3 cells for 24 h and cell viabilitywas evaluated
e to control cells from triplicate wells from 5 separate experiments (p b 0.01). Cells treated
ls and methods section.
Fig. 6. Transmission electronmicroscopy. Human insulin incubated in the absence and in the presence of 0.5MD-ribose and 5mMmethylglyoxal for 8 dayswas incubatedwith stirring at
37 °C for 24 h. The images are relative to D-ribose glycated insulin. Similar results were obtained for methylglyoxal glycated insulin.
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form. On the contrary, the MTT reduction decreased signiﬁcantly to
40% (P b 0.001)when the cells were exposed for 24 h to glycated insulin
sample. These results could suggest that glycation of insulin inhibits ﬁ-
bril formationmaintaining the protein in a pre-ﬁbrillar, highly cytotoxic
state. Alternatively, AGE adducts could be responsible per se for the cell
toxicity. To better elucidate this aspect, we performed the MTT assayFig. 7. Effect of ribose-glycated insulin on cell viability. EC were exposed for 12, 24, 48, and 72 h
evaluated byMTT assay (panel A). Data are expressed as average percentage ofMTT reduction±
morphology exposed to increasing concentration of ribose glycated insulin for 24 h (panel B). Sc
reduction.incubating the cells with glycated insulin before stirring, i.e., in condi-
tion in which the protein does not aggregate. Also in this case, the
glycated protein appeared highly cytotoxic indicating that the toxicity
is associated with the formation of the glycated adducts. Transmission
electron microscopy measurements further conﬁrmed this data (Fig.
6). Indeed, consistent with the ThT staining and the MTT assay, the
TEM images recorded at 24 h from the onset of aggregation revealedto increasing concentrations of glycated insulin (from 5 up to 60 μM) and cell viability was
SD relative to control cells from triplicatewells from 5 separate experiments (P b 0.01). EC
ale bar represents 20 μm. EC treatmentwith non-glycated insulin did not show cell viability
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preﬁbrillar aggregates were detected in the sample glycated with D-
ribose. Similar results were obtained in the presence of 5 mM
methylglyoxal.
Taken together, our results indicate that glycation of the human in-
sulin with both D-ribose and methylglyoxal strongly inhibits its ability
to form amyloid aggregates.
3.4. Cytotoxicity of ribose-glycated insulin
The cytotoxicity of glycated insulin detected on NIH-3T3 cells en-
couraged us to investigate the mechanisms underlying the toxic effect.
For this purpose, we focused our attention on endothelial cells (ECs),
an appropriate cell model to investigate the endothelial dysfunction
during diabetes and its vascular complications.
First, we evaluated the dose-dependent effect of ribose-glycated in-
sulin on EC proliferative capacity. For this purpose, cells were exposed
for 12, 24, 48, and 72 h to increasing concentrations of glycated insulin
(from 5 up to 60 μM) (Fig. 7A). The results show that ribose-glycated in-
sulin affects cell viability in a dose- and time-dependentmanner. The EC
proliferation index after treatment with lower concentrations of
glycated insulin (5–10 μM) was signiﬁcantly lower than that of the
control cells at 72 h (P b 0.05, P b 0.01). Instead, at a concentration of
20 μM, the glycated insulin affected cell viability from 24 h of incubation
(P b 0.01). Finally, EC viability resulted to be affected even after 12 h of
incubation when concentrations of glycated insulin were 40, and 60 μM
(P b 0.01).
As conﬁrmed by EC morphological evaluation, ribose-glycated
insulin is able to markedly induce cell cytoskeletal alteration (Fig. 7B).
Indeed, as a result of the treatment with ribose-glycated insulin forFig. 8. Effect of ribose-glycated insulin on cell cycle and apoptosis. ECwere treatedwith glycated
A, right)were evaluated byﬂowcytometric analysis. Caspase 3/7, caspase 8 and caspase 9were e
control. Other experimental conditions are described in the Materials and methods section.24 h, the ECs became spherical and this major morphological change
was dose-dependent. In particular, at concentrations of 30, 40, and
60 μM the EC number was also consistently reduced. This evidence
strongly supports the hypothesis that ribose-glycated insulin is highly
cytotoxic. On the basis of these results, the 30 μM concentration of
ribose-glycated insulin was chosen to further elucidate the mechanism
by which glycated insulin induces cytotoxicity.
3.5. Effect of ribose-glycated insulin on cell cycle, apoptosis and ROS
production
To study the effects on cell cycle distribution upon treatment with
glycated insulin, FACS analyses were performed (Fig. 8). EC cells were
treated with ribose-glycated insulin and a time course was carried out
for 24, 48 and 72 h.
Cell cycle analysis (Fig. 8A, left panel) displayed that glycated insulin
did not induce appreciable changes in cell cycle phases at 12 h of treat-
ment (data not shown), but it was able to signiﬁcantly alter cell cycle at
24 h of treatment. In particular, a strong reduction of cells in G1 phase
together with an increase of S phase was detected. On the other hand,
ribose-glycated insulin sensitized cells to death with an increase of
Pre-G1 phase at 48 and 72 h of treatment (20,44% and 49,43%, respec-
tively) (Fig. 8A, right panel). In order to discriminate the cell death path-
ways activated by the treatment, we monitored the enzymatic activity
of the initiator caspases 8 and 9 and of the effector caspases 3/7 using
ﬂow cytometry. The results showed that after 72 h, glycated insulin sig-
niﬁcantly activated the initiator caspase 9 in the presence of inactive
caspase 8, followed by activation of the effector caspases 3/7 (Fig. 8B).
These data suggest an involvement of the mitochondrial pathways of
apoptosis and a potential ROS activation. In line, to test whetherinsulin (30 μM) for 24, 48 and 72 h. Cell cycle (panel A, left) and pre-G1 evaluation (panel
valuated byﬂowcytometric after 72h of treatment (panel B). Cells untreatedwere used as
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glycated insulin, we measured the intracellular ROS level using the
redox-sensitive ﬂuorescent dye DCFH-DA. As shown in Fig. 9, cell expo-
sure to ribose-glycated insulin for 24, 48 and 72 h led to a signiﬁcant in-
crease in intracellular ROS compared to control cells and cells treated
with insulin alone after 72 h of exposure. Moreover, ECs were pre-
treated for 1 h with 20 mM N-acetylcysteine (NAC), a well-known
ROS inhibitor. The presence of NAC was able to strongly inhibit the
generation of intracellular ROS in cells exposed to glycated insulin to
the same level of the untreated cells (Fig. 9). Clearly, glycated insulin
promotes intracellular ROS production.
3.6. NF-kB activation by glycated insulin
Cellular effects induced by protein glycation have been reported to
be mediated by speciﬁc AGE receptors (RAGE) [48,50,54,79]. In fact,
glycation may be responsible, via RAGE, for an increase in oxidative
stress and inﬂammation through the formation of ROS and the activa-
tion of the NF-kB [80]. In its inactive state, NF-kB is maintained as a la-
tent form present in the cytoplasm where it is bound to a protein
complex that masks the nuclear localization signal. In order to check
the NF-kB involvement, we performed a confocal immunoﬂuorescent
assay on ECs incubated for 72 h with insulin and insulin glycated with
D-ribose. The results are shown in Fig. 10 A and B. Exposure of cells toFig. 9. Effect of ribose-glycated insulin on ROS production. Levels of ROSwere determined
by the DCFH-DA assay as described in Material and methods section. EC were exposed to
insulin samples (30 μM) for 24, 48 and 72 h. ROS production was also tested in the pres-
ence of NAC at 72 h. CTR: untreated cells, CTR+: cells treated with 1.0 mM H2O2, Ins:
cells treated with non-glycated insulin, InsRib: cells treated with ribose-glycated insulin.
Other experimental conditions are described in the Materials and methods section.the ribose glycated insulin resulted in NF-kB activation, as depicted by
its immunoﬂuorescence signal. Moreover, the Western blot analysis
shows a signiﬁcant 14-fold increase in the amount of NF-κB/p65 in the
nucleus (Fig. 10C).4. Discussion
Insulin plays a central role in blood glucose homeostasis and is asso-
ciated with a pathological condition termed insulin injection amyloid-
osis, characterized by the formation and deposition of amyloid ﬁbrils.
Insulin is a target of protein glycation because of its main physiological
role. Glycation has been associated with human conformational
diseases, such asAlzheimer's disease, transmissible spongiformenceph-
alopathies, and familial amyloidosis, the hallmark of which is the pres-
ence of amyloid aggregates in the affected tissues. The majority of the
cases are sporadic, suggesting that several factors must contribute to
the onset and progression of these disorders. Recently, glycation of pro-
teins has been reported to stimulate protein aggregation and amyloid
deposition [35–43]. However, the effects induced by glycation may
not be generalized since they are strongly dependent on the protein
structure and glycating agent [41].
In this paper, we ﬁrst examined the effects induced by insulin
ribosylation on the structure and ability to form amyloid aggregates,
comparing the results with those observed using methylglyoxal as
glycating agent. Our data show that AGE modiﬁcation of human insulin
slightly affects the secondary structure content which, at the end of
glycation reaction, i.e., after 7 days of incubation in the presence of
0.5 M D-ribose, consists in about 22% decrease of helical content and a
corresponding increase of unordered structure. Furthermore, the AGE-
insulin adduct does not show any predisposition to form AGE-cross-
linked oligomers as proved by native and SDS-PAGE.
However, the most relevant observation is that D-ribose modiﬁca-
tion of insulin strongly inhibits amyloid ﬁbril formation. In fact, incuba-
tion of glycated insulin under aggregating conditions produced lack of
protein aggregation, no ThT binding and a CD spectrum similar to the
one of the native protein. These results suggest that ribose-glycation
of insulin inhibits the α-helix to β-sheet transition characteristic of
the amyloid ﬁbril formation maintaining the protein in a soluble form.
Recently, Oliveira et al. [46] have analyzed the effects of methylglyoxal
on the structure, stability and ﬁbril formation of insulin. The Authors
show that the modiﬁcation of a single residue, i.e., Arg22 of the B-
chain, reduces the ability of insulin to form amyloid ﬁbrils by blocking
the formation of seeding nuclei. They proposed that a higher dynamics
in glycated insulin could lead to an impairment of the rigid cross-β
structure formation and stabilize soluble aggregates in which each
species retains a native-like structure. In our experiments, we did not
observe both formation of aggregates and AGE-cross-linked oligomers.
This could be caused by the different chemical modiﬁcations induced
by D-ribose exposure. Alternatively, the differences may be explained
by the experimental conditions used by Oliveira et al. [46]. In fact, in
their study, glycation reaction and aggregation process simultaneously
occur, thus triggering a drift from an amyloid aggregation to a native-
like aggregation pathway [46]. However, our results fully corroborate
their main conclusion that insulin glycation inhibits amyloid ﬁbril
formation. More recently, it has been reported that, using D-glucose as
glycating agent under experimental conditions similar to those
employed in our study, i.e., long-term incubation under non-reducing
condition, the glycated insulin exhibits a very low propensity for oligo-
merization [58]. The same Authors reported that, in these conditions,
amyloid-like species were not produced. However, it must be pointed
out that insulin glycation by D-glucose modiﬁes the N-terminus of
both chains and the amino group of Lys B29 on the C-terminal region
of chain B. Moreover, our observation that the extent of ﬂuorescence
quenching is largely different between D-ribose- and methylglyoxal-
insulin adducts further corroborates that the two classes of glycating
Fig. 10. Effect of ribose-glycated insulin on NF-kB activation. Representative confocal images of EC treated for 72 h with non-glycated (A) and glycated- (B) insulin (30 μM). Cells were
incubated with speciﬁc antibodies against NF-kB/p65 (red) and Vimentin (green). Scale bar represents 20 μm. Western blot analysis of NF-kB/p65 expression for cytosolic and nuclear
fractions (C). Other experimental conditions are described in the Materials and methods section.
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amino groups.
It is well established that the amyloid cytotoxicity is due to the ﬁrst
soluble oligomeric aggregates formed in the early stage of ﬁbrillation
process, whereas mature amyloid ﬁbrils are essentially harmless. The
inhibition of ﬁbril formation upon ribose-glycation could indicate that
glycation of insulin keep the protein in a pre-ﬁbrillar, highly cytotoxic
state. Our results showed that the ribose-glycated insulinwas able to af-
fect cell viability both before and after aggregating conditions, suggest-
ing that the cytotoxicity is due to the AGEs insulin adducts. This ﬁnding
was also conﬁrmed by electron microscopy images showing absence of
aggregate species in the glycated samples. In particular, the EC exposure
to ribose-glycated insulin induced an alteration in cell cycle progression
already at 24 h of treatment with a signiﬁcant cellular death at 48 and
72 h as evaluated by cytoﬂuorometry. This data was conﬁrmed by the
activation of initiator caspase 9 and effector caspase3/7 after 72 h of
treatment. Moreover, we found that the exposure of EC to ribose-
glycated insulin for 72 h generated intracellular ROS. This observation
is in line with previous reports showing that ROS production increases
in AGE-induced toxicity for several cell lines [81-84]. ROS have been
identiﬁed as signaling molecules for signal transduction of several re-
ceptors, including the cell-associated receptor for AGEs, RAGE. An im-
portant issue dealing with the signaling cascade evoked by AGE
treatment is the mechanism by which it causes oxidative stress. Previ-
ous studies indicate that AGE proteins prepared in vitro possess similar
cross-reactive AGE epitopes that are common to proteins modiﬁed by
AGEs in vivo and that interaction of these molecules with RAGE is asso-
ciated with ROS generation and NF-kB activation [55,85-88]. The tran-
scription factor NF-kB is a pleiotropic regulator of the inducible
expression of many genes and it is activated by a wide variety of stimuliassociated with stress and injury [89]. NF-kB is a dimer of two proteins
(one of which is p65) localized in the cytoplasm of un-stimulated cells
and it can be rapidly induced to enter the nucleus by appropriate signal-
ing events, including ROS production, as observed in our study. Indeed,
we found that NF-kB is activated in ECs after exposure to glycated insu-
lin. Thus, the intracellular oxidative products and the subsequent activa-
tion ofmultiple signalingmolecules, includingNF-kB, couldmediate the
effects of ribose-glycated insulin in EC cells. Additional experiments are
needed to evaluate the upstream signaling pathway and the involve-
ment of the speciﬁc receptor RAGE.
5. Conclusions
In conclusion, the present study support the concept that the effects
induced by glycation on amyloid aggregationmay not be generalized as
strongly depending on the protein structure. Indeed, being a post-
translationalmodiﬁcation, glycation can differently inﬂuence the aggre-
gation process in promoting, accelerating and/or stabilizing on-
pathway and off-pathway species. Indeed, insulin glycation with
D-ribose prevents the amyloid ﬁbril formation keeping the protein in
a soluble state. Moreover, the AGE-modiﬁed insulin when incubated
with endothelial cells induces cell dysfunction initiated by ROS produc-
tion and NF-kB activation. As observed for other glycated proteins, this
effect could be likely mediated by the interaction of AGE-modiﬁed pro-
tein with RAGE. Since accumulation of AGEs has been suggested as one
of the main responsible factors of diabetes-associated complications,
such as retinopathy, nephropathy, atherosclerosis, further examination
of the molecular bases underlying the toxic effect produced by AGE-
modiﬁed insulin on neighboring cells may help to identify new thera-
peutic interventions.
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